This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2018 Nov 13;32(17):2639-2640.

doi: 10.1097/QAD.0000000000001978.

Two cases of dolutegravir failure with R263K mutation

Margarida Cardoso¹, Teresa Baptista¹, Isabel Diogo², Maria João Aleixo³, Nuno Marques³, Kamal Mansinho¹, Perpétua Gomes^{2

4}

Affiliations

Affiliations

¹ Serviço de Doenças Infecciosas e Medicina Tropical, Hospital De Egas Moniz.
² Laboratório de Biologia Molecular, LMCBM, SPC.HEM, Centro Hospitalar Lisboa Ocidental, Lisbon.
³ Serviço de Infeciologia, Hospital Garcia de Orta.
⁴ Centro de Investigação Interdisciplinar Egas Moniz, CiiEM, ISCSEM, Almada, Portugal.

PMID: 30379690
DOI: 10.1097/QAD.0000000000001978

Case Reports

Two cases of dolutegravir failure with R263K mutation

Margarida Cardoso et al. AIDS. 2018.

. 2018 Nov 13;32(17):2639-2640.

doi: 10.1097/QAD.0000000000001978.

Authors

Margarida Cardoso¹, Teresa Baptista¹, Isabel Diogo², Maria João Aleixo³, Nuno Marques³, Kamal Mansinho¹, Perpétua Gomes^{2

4}

Affiliations

¹ Serviço de Doenças Infecciosas e Medicina Tropical, Hospital De Egas Moniz.
² Laboratório de Biologia Molecular, LMCBM, SPC.HEM, Centro Hospitalar Lisboa Ocidental, Lisbon.
³ Serviço de Infeciologia, Hospital Garcia de Orta.
⁴ Centro de Investigação Interdisciplinar Egas Moniz, CiiEM, ISCSEM, Almada, Portugal.

PMID: 30379690
DOI: 10.1097/QAD.0000000000001978

No abstract available

PubMed Disclaimer

Similar articles

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA. Brenner BG, et al. J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29. J Antimicrob Chemother. 2016. PMID: 27029845 Free PMC article.
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA. Mesplède T, et al. mBio. 2017 Apr 4;8(2):e00157-17. doi: 10.1128/mBio.00157-17. mBio. 2017. PMID: 28377526 Free PMC article.
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M. Hardy I, et al. J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3. J Antimicrob Chemother. 2015. PMID: 25281399
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.
Brenner BG, Wainberg MA. Brenner BG, et al. Virus Res. 2017 Jul 15;239:1-9. doi: 10.1016/j.virusres.2016.07.006. Epub 2016 Jul 12. Virus Res. 2017. PMID: 27422477 Review.
Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T, Wainberg MA. Mesplède T, et al. Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377. Viruses. 2014. PMID: 25166745 Free PMC article. Review.

See all similar articles

Cited by

Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.
Beck IA, Boyce CL, Bishop MD, Vu YL, Fung A, Styrchak S, Panpradist N, Lutz BR, Frenkel LM. Beck IA, et al. Viruses. 2024 Jul 19;16(7):1162. doi: 10.3390/v16071162. Viruses. 2024. PMID: 39066324 Free PMC article.
Impact of pre-existing drug resistance on risk of virological failure in South Africa.
Li JZ, Stella N, Choudhary MC, Javed A, Rodriguez K, Ribaudo H, Moosa MY, Brijkumar J, Pillay S, Sunpath H, Noguera-Julian M, Paredes R, Johnson B, Edwards A, Marconi VC, Kuritzkes DR. Li JZ, et al. J Antimicrob Chemother. 2021 May 12;76(6):1558-1563. doi: 10.1093/jac/dkab062. J Antimicrob Chemother. 2021. PMID: 33693678 Free PMC article.
Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.
Pena MJ, Chueca N, D'Avolio A, Zarzalejos JM, Garcia F. Pena MJ, et al. Open Forum Infect Dis. 2018 Dec 10;6(1):ofy332. doi: 10.1093/ofid/ofy332. eCollection 2019 Jan. Open Forum Infect Dis. 2018. PMID: 30631792 Free PMC article.
Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Braun DL, Scheier T, Ledermann U, Flepp M, Metzner KJ, Böni J, Günthard HF. Braun DL, et al. Viruses. 2020 Nov 19;12(11):1330. doi: 10.3390/v12111330. Viruses. 2020. PMID: 33228206 Free PMC article.
A systematic review of the genetic mechanisms of dolutegravir resistance.
Rhee SY, Grant PM, Tzou PL, Barrow G, Harrigan PR, Ioannidis JPA, Shafer RW. Rhee SY, et al. J Antimicrob Chemother. 2019 Nov 1;74(11):3135-3149. doi: 10.1093/jac/dkz256. J Antimicrob Chemother. 2019. PMID: 31280314 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- Stanford HIV Drug Resistance Database